Now showing items 1-8 of 8

  • Deficiency of the B cell-activating factor receptor results in limited CD169+ macrophage function during viral infection 

    Xu, H. C.; Huang, J.; Khairnar, V.; Duhan, V.; Pandyra, A. A.; Grusdat, M.; Shinde, P.; McIlwain, D. R.; Maney, S. K.; Gommerman, J.; Löhning, M.; Ohashi, P. S.; Mak, T. W.; Pieper, K.; Sic, H.; Speletas, M.; Eibel, H.; Ware, C. F.; Tumanov, A. V.; Kruglov, A. A.; Nedospasov, S. A.; Häusinger, D.; Recher, M.; Lang, K. S.; Lang, P. A. (2015)
    The B cell-activating factor (BAFF) is critical for B cell development and humoral immunity in mice and humans. While the role of BAFF in B cells has been widely described, its role in innate immunity remains unknown. Using ...
  • Efficacy of Interferon A-2b Monotherapy in B-Thalassemics with Chronic Hepatitis C 

    Kalafateli, M.; Kourakli, A.; Gatselis, N.; Lambropoulou, P.; Thomopoulos, K.; Tsamandas, A.; Christofidou, M.; Zachou, K.; Jelastopoulou, E.; Nikolopoulou, V.; Symeonidis, A.; Dalekos, G. N.; Lambropoulou-Karatza, C.; Triantos, C. (2015)
    Background & Aims: Monotherapy with standard or pegylated interferon (PegIFN) remains the first-line treatment for HCV infection in patients with thalassemia major (beta TM), although its long-term impact is still unknown. ...
  • Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study 

    Anagnostou, O.; Manolakopoulos, S.; Bakoyannis, G.; Papatheodoridis, G.; Zisouli, A.; Raptopoulou-Gigi, M.; Manesis, E.; Ketikoglou, I.; Dalekos, G.; Gogos, C.; Vassiliadis, T.; Tzourmakliotis, D.; Karatapanis, S.; Kanatakis, S.; Zoumpoulis-Vafiadis, I.; Hounta, A.; Koutsounas, S.; Giannoulis, G.; Tassopoulos, N.; Touloumi, G. (2014)
    Background and aim: Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece ...
  • Melanoma: The Radiotherapeutic point of view; review of the current literature 

    Zygogianni, A.; Kyrgias, G.; Kouvaris, J.; Mystakidou, K.; Gogas, H.; Kouloulias, V. (2011)
    Surgery remains the mainstay of melanoma therapy at all sites. Melanoma is widely believed to be a radioresistant tumor, a misconception that has historically led to the limited use of RT for its treatment. We searched ...
  • New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment 

    Dastiridou, A.; Kalogeropoulos, C.; Brazitikos, P.; Symeonidis, C.; Androudi, S. (2012)
    Current treatment guidelines for chronic ocular inflammatory disease recommend the use of steroid-sparing agents. The development of conventional immunomodulatory agents has largely changed the visual outcome in these ...
  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection 

    Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)
    Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ...
  • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

    Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
    The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...
  • Vascular endothelial growth factor (VEGF) in pleural effusions 

    Kiropoulos, T. S.; Daniil, Z.; Gourgoulianis, K. I.; Zakynthinos, E. (2007)
    Pleural effusion is a common clinical problem in everyday clinical practice. Vascular endothelial growth factor (VEGF) is a 34-45 kDa homodimeric glycoprotein, which is a potent mediator of angiogenesis and vascular ...